Neogen Q1 Earnings Miss Estimates, Revenues Beat, Stock Climbs

Core Insights - Neogen Corporation (NEOG) reported first-quarter fiscal 2026 adjusted earnings per share (EPS) of 4 cents, missing the Zacks Consensus Estimate by 20% and reflecting a 42.9% decline from the previous year [1][10] - Revenues for the quarter decreased 3.6% year-over-year to $209.2 million, with core revenues increasing by 0.3% [2][10] - Following the earnings announcement, NEOG stock rose by 16.5% to close at $6.78 [2] Revenue Breakdown - The Food Safety segment generated revenues of $152.1 million, a 4.6% decrease year-over-year, with a core revenue decline of 1.7% [3][4] - The Animal Safety segment reported revenues of $57.1 million, down 0.8% year-over-year, but core revenues increased by 5.8% [5] - The Genomics business returned to positive core revenue growth in the mid-single-digit range [6] Margin and Expense Analysis - Gross profit declined 9.5% year-over-year to $95 million, with gross margin contracting by 296 basis points to 45.4% [7] - Sales and marketing expenses were $45 million, down 1.6% year-over-year, while administrative expenses increased by 17.8% to $61 million [8] Cash Position and Liabilities - Neogen's cash and cash equivalents at the end of the first quarter totaled $138.9 million, up from $129 million at the end of the previous quarter [9] - The company has total outstanding debt of $800 million and a committed borrowing headroom of $201.5 million [9] Fiscal 2026 Outlook - Neogen reaffirmed its fiscal 2026 revenue projections of $820-$840 million, with adjusted EBITDA expected to be between $165 million and $175 million [11][10] - Capital expenditures are projected to be around $50 million [11] Performance Summary - The company ended the first quarter with mixed results, as earnings missed expectations while revenues exceeded estimates [12] - Execution challenges have impacted performance, but the company is focusing on commercial excellence and cost structure improvements [12][13]